Abivax SA announced that four scientific abstracts on its lead drug candidate, obefazimod, for the treatment of moderately to severely active ulcerative colitis (UC) and in a preclinical model on colon cancer, will be presented at Digestive Disease Week (DDW) as part of scientific exchange, taking place May 18-21, 2024, in Washington D.C., U.S.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.08 EUR | +0.62% | +6.69% | +33.20% |
May. 20 | BTIG Initiates Abivax at Buy Rating With $43 Price Target | MT |
May. 08 | Abivax: four abstracts to be presented on obefazimod | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.20% | 879M | |
+49.21% | 56.95B | |
+39.98% | 40.26B | |
-6.86% | 39.32B | |
-4.42% | 28.37B | |
+12.00% | 26.45B | |
-18.27% | 19.41B | |
+29.57% | 12.54B | |
+25.41% | 12.21B | |
-0.35% | 12.15B |
- Stock Market
- Equities
- ABVX Stock
- News Abivax
- Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024